Olema Pharmaceuticals, Inc.
OLMA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001750284
In the last 90 days, Olema Pharmaceuticals, Inc. insiders filed 0 open-market purchases and 1 sale; 185 institutions reported holding it in 13F filings for Q2 2026, worth $1.28B in total; Duquesne Family Office is the only superinvestor holding it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $291.2K in total
- 1
- 13F holdersQ2 2026, −8 vs. previous quarter
- 185
- 13F valueReported value at the end of Q2 2026
- $1.28B
- Superinvestors holdingAt the end of Q2 2026
- 1
Price chart
Superinvestors holding OLMA, Q2 2026
1 superinvestor reports holding Olema Pharmaceuticals, Inc. on Form 13F. Percentages are the stock's share of each portfolio.
Duquesne Family Office
Stanley Druckenmiller
0.3%
Olema Pharmaceuticals, Inc.'s share of the portfolio
- Shares
- 986,827
- Value
- $12.3M
Latest insider trades
Open-market purchases and sales by Olema Pharmaceuticals, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 27, 2026 (view filing)7:30 PM ET | Jul 23-24 | 4 days | Harmon CyrusDirector | SSale | −25.0K | $11.65 | −$291.2K | −3.4%702.8K after | 2 lots |
| Mar 5, 2026 (view filing) | Mar 3-4 | 2 days | Mitchell ShawnteCHIEF LEGAL OFFICER | SSale | −39.8K | $23.78 | −$945.7K | −99.4%233 after | 2 lots |
| Mar 5, 2026 (view filing) | Mar 4 | 1 day | Mitchell ShawnteCHIEF LEGAL OFFICER | SSaleComon Stock | −233 | $24.69 | −$5.75K | −100.0%0 after | |
| Jan 21, 2026 (view filing) | Jan 20 | 1 day | Harmon CyrusDirector | SSale | −10.0K | $26.88 | −$268.8K | −1.4%727.8K after | |
| Jan 16, 2026 (view filing) | Jan 14 | 2 days | Harmon CyrusDirector | SSale | −3.49K | $29.12 | −$101.6K | −0.5%737.8K after | |
| Jan 15, 2026 (view filing) | Jan 13-15 | 2 days | Kovacs Shane William CharlesCH. OPERATING & FINANCIAL OFF. | SSale | −103.8K | $28.70 | −$2.98M | −42.6%139.7K after | 2 lots |
| Jan 14, 2026 (view filing) | Jan 12 | 2 days | Myles David C.CH. DISCOV. & NON-CLIN DEV OFF | SSale | −10.0K | $28.34 | −$283.4K | −6.5%144.8K after | |
| Jan 14, 2026 (view filing) | Jan 13-14 | 1 day | Myles David C.CH. DISCOV. & NON-CLIN DEV OFF | SSale | −100.0K | $28.24 | −$2.82M | −15.6%542.8K after | 4 lots |
| Dec 29, 2025 (view filing) | Dec 22 | 7 days | Harmon CyrusDirector | SSale | −2.88K | $28.53 | −$82.2K | −0.4%741.3K after | |
| Dec 23, 2025 (view filing) | Dec 19-23 | 4 days | Zojwalla NaseemChief Medical Officer | SSale | −269.5K | $27.94 | −$7.53M | −98.4%4.49K after | 4 lots |
Top 10 13F holders, Q2 2026
The largest institutional positions in Olema Pharmaceuticals, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| FMR LLC | 12,143,062 | $151.9M | 0.01% | +1,756,217+16.9% | Added |
| Paradigm Biocapital Advisors LP | 8,670,576 | $108.5M | 2.03% | +650,000+8.1% | Added |
| Jupiter Topco LLC | 7,094,413 | $88.8M | 0.04% | +7,094,413 | New |
| Bain Capital Life Sciences Investors, LLC | 7,085,249 | $88.6M | 5.27% | −387,989−5.2% | Reduced |
| BlackRock, Inc. | 6,714,691 | $84.0M | 0.00% | +1,062,556+18.8% | Added |
| BVF Inc | 5,295,893 | $66.3M | 1.69% | 00.0% | Unchanged |
| Siren, L.L.C. | 4,856,949 | $60.8M | 1.23% | +100,000+2.1% | Added |
| State Street Corp | 4,316,058 | $54.0M | 0.00% | +378,227+9.6% | Added |
| Vanguard Capital Management LLC | 3,341,217 | $41.8M | 0.00% | +257,700+8.4% | Added |
| Logos Global Management LP | 3,208,875 | $40.1M | 1.73% | 00.0% | Unchanged |